Ariad Pharmaceuticals Inc fka ARIA

[LUMA14]

Early TKI Responses Predict CML Survival, Especially With Dasatinib

link to article

Two studies presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago, show that early deep responses with tyrosine kinase inhibitors (TKIs) yield lasting positive outcomes in chronic myeloid leukemia (CML) patients, and that dasatinib offers a better chance at such responses over imatinib.

Previous work has already suggested that early cytogenetic and molecular responses can lead to good outcomes in CML. “Landmark analyses are limited for CML patients treated with multiple prior TKIs, and the association between deep, early responses and long-term outcomes is not well established,” wrote authors of one of the studies (abstract 7053) led by Martin C. Müller, MD, of the Universitätsmedizin Mannheim in Germany, in a poster presentation.

That study evaluated the impact of early response to ponatinib in heavily pretreated patients participating in the ongoing PACE trial. It included 267 patients, most of whom (61%) had been treated with at least three prior TKIs; most patients (61%) had developed resistance to dasatinib or nilotinib.